Carl Haslam

Carl Haslam is a Senior Scientist in Biochemistry at Artios Pharma Ltd, where the focus is on developing next-generation DNA damage and repair drugs since August 2021. Prior experience includes serving as a Senior Scientist at GSK from January 2002 to August 2021, a Research Scientist at Novartis from 1997 to 2002, and a Clinical Chemistry Scientist at Ciba-Geigy from August 1989 to July 1995. Carl Haslam holds an MSc in Biomedical Sciences from King's College London, completed between 2004 and 2006.